Skip to content

In the BioHarmony Drug Report Database

Pimavanserin

Nuplazid (pimavanserin) is a small molecule pharmaceutical. Pimavanserin was first approved as Nuplazid on 2016-04-29. It is used to treat hallucinations, parkinson disease, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. Nuplazid's patents are valid until 2038-08-27 (FDA).
Trade Name Nuplazid
Common Name Pimavanserin
Indication hallucinations, parkinson disease, schizophrenia spectrum and other psychotic disorders
Drug Class Serotonin 5-HT2 receptor antagonists
Pimavanserin
Get full access now